Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

Bempegaldesleukin Plus Nivolumab Granted Breakthrough Designation in Melanoma by the FDA

The combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) was granted a breakthrough therapy designation by the FDA for the treatment of patients with previously untreated unresectable or metastatic melanoma.


Posted in Melanoma News, Regulatory, Publications

Hairdressers are willing to help customers detect skin cancers

(Reuters Health) – Most hair stylists at salons and barber shops may be interested in getting trained to detect skin cancers on the scalp, face and neck, researchers say.


Posted in Melanoma News, Patients, Latest News

Nivolumab Demonstrates Durable Long-term Survival in Patients with Advanced Cancers

Treatment with nivolumab demonstrated durable survival in previously-treated patients with advanced melanoma, renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC), according to a new study published in JAMA Oncology.


Posted in Melanoma News, Health Professionals, Of Interest

Personalized Vaccine Shows Protective Benefit Against Disease Recurrence in High-Risk Melanoma

A personalized therapeutic cancer vaccine being developed by Elios Therapeutics for patients with high-risk melanoma demonstrated positive results in a phase 2b clinical trial, according to a press release. 


Posted in Melanoma News, Health Professionals, Of Interest